- Home
- RS vs RPRX Comparison
RS vs RPRX Comparison
Compare RS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RS | RPRX |
|---|---|---|
| Founded | 1939 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 16.2B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RS | RPRX |
|---|---|---|
| Price | $284.89 | $39.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $317.25 | $46.00 |
| AVG Volume (30 Days) | 297.8K | ★ 4.3M |
| Earning Date | 10-22-2025 | 11-05-2025 |
| Dividend Yield | 1.68% | ★ 2.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 13.63 | 1.75 |
| Revenue | ★ $13,922,300,000.00 | $2,349,844,000.00 |
| Revenue This Year | $5.75 | $37.13 |
| Revenue Next Year | $4.42 | $1.48 |
| P/E Ratio | ★ $20.97 | $22.68 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $250.07 | $24.05 |
| 52 Week High | $347.44 | $41.24 |
Technical Indicators
Market Signals| Indicator | RS | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.21 | 57.50 |
| Support Level | $275.00 | $39.24 |
| Resistance Level | $289.53 | $40.50 |
| Average True Range (ATR) | 6.90 | 0.91 |
| MACD | 1.87 | -0.08 |
| Stochastic Oscillator | 84.30 | 76.02 |
Price Performance
Historical ComparisonAbout RS Reliance Steel & Aluminum Co. (DE)
Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.